Welcome to our dedicated page for Ocugen SEC filings (Ticker: OCGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Ocugen, Inc. (NASDAQ: OCGN) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents are central for understanding Ocugen’s development plans in gene therapies for blindness diseases, its financial condition, and key corporate actions.
Ocugen uses Form 8‑K current reports to announce material events, including exclusive licensing agreements, registered direct offerings of common stock and warrants, litigation developments, and Nasdaq listing compliance updates. For example, recent 8‑K filings describe an exclusive license agreement with Kwangdong Pharmaceutical Co., Ltd. for OCU400 in the Republic of Korea, a securities purchase agreement for a registered direct offering, and court decisions related to a securities class action lawsuit.
Periodic reports such as Form 10‑Q and Form 10‑K (when available) provide more comprehensive information on Ocugen’s financial results, operating expenses, and risk factors. In a recent earnings-related press release furnished on Form 8‑K, the company detailed revenue from collaborative arrangements, research and development expenses, general and administrative expenses, and net loss figures, along with commentary on cash runway and financing plans.
Investors can also review filings that discuss executive compensation and equity awards, such as performance restricted stock units granted to senior leadership, and agreements related to licensing, supply, and regional commercialization of products like OCU400. These filings help clarify how management is incentivized and how Ocugen structures partnerships around its modifier gene therapy platform.
On Stock Titan, Ocugen’s SEC filings are updated in near real time from the EDGAR system. AI-powered tools summarize lengthy documents, highlight key sections on clinical programs, licensing terms, capital raises, and governance matters, and make it easier to locate items such as quarterly results, material agreements, and other disclosures relevant to OCGN stock.
Ocugen, Inc. director Zhang Junge exercised stock options to acquire additional common shares. On April 1, 2026, he exercised options covering 194,134 shares of common stock at exercise prices of $0.51, $0.46, and $1.42 per share. Following these exercises, he directly owns 1,359,316 common shares. The options had previously vested and become exercisable between January 2020 and June 2025.
Ocugen Inc common stock ownership filing shows The Vanguard Group reports zero beneficial ownership and 0% of the class. The filing explains an internal realignment of Vanguard effective January 12, 1998 that led certain subsidiaries to report separately. The form is signed by Ashley Grim on 03/27/2026.
Ocugen, Inc. furnished an investor presentation outlining progress in its gene therapy pipeline for blinding retinal diseases. The company is targeting three biologics license applications over three years for retinitis pigmentosa, Stargardt disease, and geographic atrophy.
OCU400 for retinitis pigmentosa is in Phase 3 with enrollment completed; Phase 1/2 data showed durable visual function gains over three years and no related severe adverse events, with 88% of treated evaluable subjects showing improvement or preservation versus untreated eyes. OCU410ST for Stargardt disease has initiated a pivotal Phase 2/3 trial after Phase 1 data showed atrophic lesion growth 54% slower and visual function stabilized or improved in all treated eyes.
OCU410 for geographic atrophy delivered positive preliminary 12‑month Phase 2 results, including a 31% reduction in lesion size and 27% slower ellipsoid zone loss at the medium dose compared with controls, with no serious or special-interest adverse events deemed related to OCU410. Ocugen plans to start a global Phase 3 GA trial and progress rolling BLA submissions as key upcoming milestones.
Ocugen, Inc. reported positive 12‑month topline Phase 2 ArMaDa data for OCU410, its modifier gene therapy for geographic atrophy secondary to dry age‑related macular degeneration. The optimal medium dose showed a 31% reduction in GA lesion growth versus control at 12 months and a 27% slower loss of the ellipsoid zone, a structural marker linked to visual function. Across treated patients there were no OCU410‑related serious adverse events or adverse events of special interest, supporting a favorable safety and tolerability profile. Based on these results, Ocugen plans to initiate a global Phase 3 registrational trial of OCU410 with up to 300 subjects in the third quarter of 2026, as part of its broader goal of three biologics license applications in three years.
Ocugen, Inc. reports that an institutional investor partially exercised previously issued warrants and purchased 10,000,000 shares of common stock on March 12, 2026. This warrant exercise generated gross proceeds of $15.0 million for Ocugen. The company states that, based on this cash infusion, it now anticipates its cash runway will extend into the first quarter of 2027, supporting ongoing operations and development plans.
Ocugen, Inc. Chief Financial Officer Treerita Essalima Johnson-Greene filed an initial statement of beneficial ownership. The filing reports 750,000 options to buy Ocugen stock and 500,000 common shares held directly, plus 350 common shares held indirectly by a spouse.
The reported option vests in equal annual installments over three years beginning on February 17, 2027, subject to continued service with the company on each vesting date. This filing establishes the CFO’s starting equity position as a reporting insider.
Ocugen, Inc. is a late-stage biotechnology company focused on gene therapies and biologics for serious eye diseases, a regenerative knee cartilage implant, and an inhaled mucosal vaccine platform. Its lead modifier gene therapy, OCU400 for retinitis pigmentosa, has completed Phase 3 enrollment of 140 subjects, with a rolling BLA planned to begin in the third quarter of 2026 and topline data expected in the first quarter of 2027. Long-term Phase 1/2 data show approximately 2-line LLVA gains and durable safety across multiple mutations.
OCU410 and OCU410ST, both based on the RORA gene, target geographic atrophy and Stargardt disease, respectively. Phase 2 ArMaDa data for OCU410 showed a 46% reduction in lesion growth at 12 months versus control and a favorable safety profile, while Phase 1 GARDian1 data for OCU410ST showed atrophic lesion growth 54% slower at 12 months in treated eyes and 100% stabilization or improvement in visual function among evaluable treated eyes. A 51-patient Phase 2/3 pivotal trial for OCU410ST is underway, with enrollment expected to complete in early 2026 and a BLA submission planned in the first half of 2027.
The company is also developing OCU200, a fusion protein for DME, DR, and wet AMD now in a multicenter Phase 1 trial, and NeoCart, a Phase 3-ready autologous knee cartilage implant held in its OrthoCellix subsidiary. Its inhaled COVID-19 vaccine candidate OCU500 will enter a Phase 1 trial funded by NIAID’s Project NextGen, and Ocugen reports 80 patents and 66 pending applications worldwide supporting its pipeline and partnered programs.
Ocugen, Inc. has filed an 8-K describing a petition to the Delaware Court of Chancery under Section 205 of the Delaware General Corporation Law. The company asks the court to validate a charter amendment that increased authorized common shares from 295,000,000 to 390,000,000 and to confirm the validity of shares issued based on that change.
The petition follows a stockholder lawsuit challenging whether special Series C preferred stock could vote on the 2024 share increase proposal. Ocugen states it acted in good faith, that a correction filing fixed any drafting issue, and that about 33,009,874 shares have been issued in reliance on the amendment. A hearing on the petition is scheduled for May 6, 2026, and the stockholder plaintiff does not oppose the requested relief.
Ocugen, Inc. reported fourth quarter and full year 2025 results and a broad business update focused on its gene therapy pipeline. For 2025, total revenue was $4,413 thousand while operating expenses reached $67,329 thousand, leading to a net loss of $67,846 thousand, wider than 2024. Cash, cash equivalents and restricted cash fell to roughly the high teens in millions of dollars, and total stockholders’ equity turned negative.
Clinically, enrollment is complete in the 140-patient Phase 3 liMeliGhT trial of OCU400 for retinitis pigmentosa, with topline data planned in the first quarter of 2027 to support a Biologics License Application. OCU410 for geographic atrophy showed preliminary Phase 2 results including a 46% reduction in lesion growth versus control at 12 months and a 60% slower rate of ellipsoid zone loss in treated eyes. Management is targeting three BLA submissions for OCU400, OCU410ST and OCU410 between 2026 and 2028. To bolster liquidity, Ocugen completed a $22.5 million underwritten registered direct offering in January 2026 and notes it may receive up to an additional $30 million if previously issued warrants are exercised, which together underpin guidance for a cash runway into at least the fourth quarter of 2026.
Ocugen, Inc. appointed Rita Johnson-Greene as Chief Financial Officer effective February 9, 2026, with her role as principal financial officer beginning after the filing of the Annual Report for the year ended December 31, 2025. Current principal financial officer Ramesh Ramachandran will continue as Chief Accounting Officer and principal accounting officer.
Under her employment agreement, Ms. Johnson-Greene will receive a $440,000 annual base salary, an initial target bonus opportunity of up to 45% of base salary, and a $90,000 sign-on bonus subject to repayment if she departs within one year. She was granted options to purchase 750,000 shares of common stock and 500,000 restricted stock units that vest in equal annual installments over three years. The agreement includes 12 months of salary continuation and COBRA premium support upon certain terminations, with additional bonus and full equity vesting acceleration if such a termination occurs around a change in control.